oxaliplatin / Generic mfg. |
NCT00263055: MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV |
|
|
| Completed | 4 | | RoW | oxaliplatin | Sanofi | Colonic Neoplasms | 06/05 | | | |
NCT00869271: Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer |
|
|
| Completed | 4 | 200 | RoW | tac + folfox4, Folfox4 | Fudan University | Unresectable Liver Metastasis of Colorectal Cancer | 12/07 | 12/07 | | |
NCT00868816: Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles |
|
|
| Completed | 4 | 400 | RoW | 12 cycles of oxaliplatine based adjuvant chemotherapy, 8 cycles of oxaliplatine based adjuvant chemotherapy | Fudan University | Colorectal Cancer | 12/07 | 12/07 | | |
NCT00129870: CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer |
|
|
| Terminated | 4 | 180 | US | oxaliplatin | Sanofi | Colorectal Cancer | | 12/07 | | |
NCT00559676: Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer |
|
|
| Completed | 4 | 200 | Europe | capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, laboratory biomarker analysis, pharmacological study | Centre Hospital Regional Universitaire de Limoges | Colorectal Cancer | 05/11 | | | |
NCT00577031 / 2007-004969-18: OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. |
|
|
| Completed | 4 | 205 | Europe | bevacizumab [Avastin], Oxaliplatin, Xeloda | Hoffmann-La Roche | Colorectal Cancer | 08/11 | 08/11 | | |
|
NCT01468623: Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 |
|
|
| Terminated | 4 | 51 | US | Pharmacokinetic 5-FU dose adjustment using OnDose® assay, OnDose®, Standard of care | Myriad Genetic Laboratories, Inc. | Colorectal Cancer, Metastatic | 08/12 | 08/12 | | |
NCT02284529: Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer |
|
|
| Completed | 4 | 20 | RoW | Orectalip, Fluorouracil, Leucovorin | Sinphar Pharmaceutical Co., Ltd, Taichung Veterans General Hospital | Stage-Ⅱ Colorectal Cancer | 08/14 | 09/14 | | |
| Completed | 4 | 83 | Europe | Evaluate the correlation of overall different objective response. | Grupo Espanol Multidisciplinario del Cancer Digestivo | Colorectal Cancer, Hepatic Metastasis | 12/14 | 12/17 | | |
ASCENT, NCT01588990: A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer |
|
|
| Completed | 4 | 128 | RoW | Oxaliplatin, Capecitabine, Bevacizumab, Avastin, RO4876646, Leucovorin, 5-Fluouracil, Irinotecan | Hoffmann-La Roche | Colorectal Neoplasms | 09/16 | 09/16 | | |